OUTPACE Trademark

Therapeutics for use in the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, genetic disorders and other human diseases; cell therapies, in the nature of modified cells, engineered cells, therapeutic agents, and their delivery agents, for the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders; biopharmaceuticals for use in the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders; medicines for use in the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders; medical preparations for use in the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders; pharmaceutical products for use in the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders; pharmaceutical preparations for the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders; therapeutic pharmaceuticals for use in the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders; therapeutic agents for use in the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders; biologics in the nature of cells for use in the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, genetic disorders and other human diseases; biologics in the nature of viral vectors for use in the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, genetic disorders and other human diseases; biologic preparations for use in the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders; cells for medical or clinical purposes; viral or non-viral delivery vectors, namely, delivery agents for treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders; therapeutic proteins for medical or clinical purposes; antibodies and libraries of antibodies for medical purposes; pharmaceutical preparations for cell therapy for the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorder, and genetic disorders; pharmaceutical preparations for targeted cell therapy for the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders; pharmaceutical products for cellular therapy for the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders; gene therapy products, namely, genetically engineered cells, cell components, molecules, proteins and protein complexes; therapeutic preparations, namely, therapeutic antigens for medical purposes and antibodies for medical purposes; engineered cells for medical use; bioengineered cells for medical use; biological preparations for use in cell engineering platforms cultures for medical purposes; biological preparations for use in protein design platforms for medical purposes; biological preparations designed by computational protein platforms for medical purposes; biological preparations designed by AI-powered protein design platforms for medical purposes; pharmaceutical preparations developed with a computational protein design platform for the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders; pharmaceutical preparations developed with AI-powered protein design platforms for the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, genetic disorders; pharmaceutical preparations for medical or clinical purposes, namely, for the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders; pharmaceutical preparations comprised of cells, cell components, molecules, and viruses for medical or clinical purposes, namely, for the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders; pharmaceutical preparations comprised of gene delivery vectors for medical or clinical purposes, namely, for the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders; pharmaceutical preparations comprised of proteins for medical or clinical purposes, in particular for the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders;